Rampart Investment Management Company Cut By $326,826 Its Rockwell Collins (COL) Stake; 4 Analysts Bullish Arrowhead Pharmaceuticals, Inc. (ARWR)

September 14, 2018 - By Rene Emery

Rockwell Collins, Inc. (NYSE:COL) Logo

Among 4 analysts covering Arrowhead Pharmaceuticals (NASDAQ:ARWR), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arrowhead Pharmaceuticals had 8 analyst reports since March 27, 2018 according to SRatingsIntel. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has “Buy” rating given on Thursday, September 6 by FBR Capital. The rating was maintained by FBR Capital on Tuesday, March 27 with “Hold”. FBR Capital maintained the stock with “Neutral” rating in Wednesday, August 8 report. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Buy” rating by Cantor Fitzgerald on Monday, June 18. Cantor Fitzgerald upgraded the shares of ARWR in report on Wednesday, May 9 to “Overweight” rating. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has “Buy” rating given on Wednesday, May 30 by Cantor Fitzgerald. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Buy” rating by Chardan Capital Markets on Thursday, September 6. See Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) latest ratings:

06/09/2018 Broker: Chardan Capital Markets Old Rating: Buy New Rating: Buy Old Target: $17.5 New Target: $24.5 Maintain
06/09/2018 Broker: FBR Capital Old Rating: Neutral New Rating: Buy Old Target: $18 Upgrade
08/08/2018 Broker: FBR Capital Old Rating: Neutral New Rating: Neutral Old Target: $12 New Target: $18 Maintain
18/06/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $13.0000 Maintain
30/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $13.0000 Maintain
09/05/2018 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Overweight Old Target: $5 Upgrade
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $4.0000 Maintain
27/03/2018 Broker: Jefferies Rating: Buy New Target: $10 Initiates Coverage On

Rampart Investment Management Company Llc decreased Rockwell Collins Inc (COL) stake by 39.91% reported in 2018Q2 SEC filing. Rampart Investment Management Company Llc sold 2,439 shares as Rockwell Collins Inc (COL)’s stock rose 1.03%. The Rampart Investment Management Company Llc holds 3,672 shares with $495,000 value, down from 6,111 last quarter. Rockwell Collins Inc now has $23.18B valuation. The stock increased 0.99% or $1.38 during the last trading session, reaching $141.04. About 1.81 million shares traded or 65.06% up from the average. Rockwell Collins, Inc. (NYSE:COL) has risen 6.18% since September 14, 2017 and is uptrending. It has underperformed by 9.44% the S&P500. Some Historical COL News: 19/03/2018 – BOEING – FOLLOWING PRODUCTIVE DISCUSSIONS, REACHED “WIN-WIN AGREEMENTS” WITH UNITED TECHNOLOGIES & ROCKWELL COLLINS; 19/03/2018 – United Technologies CEO Eyes Exit After Rockwell Integration; 22/03/2018 – AIR TAHITI NUI – PHASING OUT OF CO’S CURRENT AIRBUS A340-300 FLEET TO COMMENCE IN NOV, BE COMPLETED BY SEPT 2019; 14/05/2018 – ROCKWELL LAND CORP ROCK.PS – QTRLY NET INCOME ATTRIBUTABLE TO EQUITY HOLDERS OF ROCKWELL LAND CORP 620 MLN PESOS VS 516 MLN PESOS; 04/05/2018 – UNITED TECH WILL REVIEW OPS PORTFOLIO AFTER ROCKWELL DEAL: CNBC; 02/05/2018 – Alastair Macdonald: Exclusive: #UTC set to win #EU approval for $23 billion Rockwell Collins deal; 24/04/2018 – UNITED TECH SAYS CONTINUE TO SEE A CLOSE OF ROCKWELL COLLINS DEAL BY MID-YEAR; SAYS WORKING CLOSELY WITH REGULATORS TO COMPLETE REMAINING REVIEWS – CONF CALL; 04/05/2018 – UTC gets European go-ahead for $23 billion purchase of Rockwell Collins; 27/04/2018 – Rockwell Collins Discloses Investigation Into Employee Entertainment Expenses Before B/E Aerospace Buyout — MarketWatch; 05/04/2018 – Judge Allows Berkshire Museum to Sell Rockwell Painting and Other Works

Analysts await Rockwell Collins, Inc. (NYSE:COL) to report earnings on October, 26. They expect $2.02 EPS, up 12.22% or $0.22 from last year’s $1.8 per share. COL’s profit will be $332.02 million for 17.46 P/E if the $2.02 EPS becomes a reality. After $1.73 actual EPS reported by Rockwell Collins, Inc. for the previous quarter, Wall Street now forecasts 16.76% EPS growth.

Investors sentiment increased to 0.87 in Q2 2018. Its up 0.12, from 0.75 in 2018Q1. It is positive, as 41 investors sold COL shares while 186 reduced holdings. 50 funds opened positions while 148 raised stakes. 105.25 million shares or 0.83% more from 104.39 million shares in 2018Q1 were reported. Cedar Hill Lc holds 0.08% or 3,015 shares. Toronto Dominion Natl Bank stated it has 0.03% of its portfolio in Rockwell Collins, Inc. (NYSE:COL). 77,063 were accumulated by Retirement Systems Of Alabama. Cetera Advisor Net Ltd Limited Liability Company has invested 0.02% in Rockwell Collins, Inc. (NYSE:COL). Zeke Ltd stated it has 0.04% in Rockwell Collins, Inc. (NYSE:COL). Choate Inv Advsrs holds 0.02% or 2,246 shares. Da Davidson And has 0.02% invested in Rockwell Collins, Inc. (NYSE:COL). Walleye Trading Ltd Liability Corp stated it has 160,623 shares or 0.12% of all its holdings. Klingenstein Fields And Co Limited Co has 0.18% invested in Rockwell Collins, Inc. (NYSE:COL). Lombard Odier Asset Management (Europe) Ltd invested in 0.02% or 1,894 shares. California-based Fuller And Thaler Asset Mgmt has invested 0% in Rockwell Collins, Inc. (NYSE:COL). National Pension Ser stated it has 0.11% of its portfolio in Rockwell Collins, Inc. (NYSE:COL). Btim holds 44,773 shares. Ftb Advsr Inc invested in 630 shares. United Kingdom-based Aviva Public Limited Co has invested 0.09% in Rockwell Collins, Inc. (NYSE:COL).

Rampart Investment Management Company Llc increased Ventas Inc (NYSE:VTR) stake by 26,348 shares to 30,160 valued at $1.72M in 2018Q2. It also upped Cbre Group Inc (NYSE:CBG) stake by 22,939 shares and now owns 205,692 shares. Anadarko Pete Corp (NYSE:APC) was raised too.

The stock increased 3.00% or $0.55 during the last trading session, reaching $18.88. About 807,357 shares traded. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has risen 456.10% since September 14, 2017 and is uptrending. It has outperformed by 440.48% the S&P500. Some Historical ARWR News: 14/05/2018 – Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV; 24/04/2018 – Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results; 11/04/2018 – Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™; 30/05/2018 – Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV; 30/05/2018 – ARROWHEAD PHARMACEUTICALS INC – INTENDS TO SUBMIT A LATE-BREAKING ABSTRACT WITH INITIAL CLINICAL DATA ON ARO-HBV; 01/05/2018 – Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics; 12/03/2018 – Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease; 09/04/2018 – Sunroc Corporation Announces Acquisition of Arrowhead Concrete Assets of Wyoming Concrete Company Acquired; 14/05/2018 – ARROWHEAD DOSES PATIENTS IN PHASE 1/2 STUDY OF ARO-HBV; 27/03/2018 – Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $1.66 billion. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It currently has negative earnings. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.

More important recent Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on September 07, 2018, also Seekingalpha.com published article titled: “Arrowhead Pharmaceuticals Could Become The Next Gilead”, Seekingalpha.com published: “Arrowhead’s HBV candidate shows positive action in early-stage study; shares up 16% premarket” on September 06, 2018. More interesting news about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) was released by: Benzinga.com and their article: “Mid-Day Market Update: NASDAQ Down Over 1%; WSI Industries Shares Spike Higher” with publication date: September 06, 2018.

Rockwell Collins, Inc. (NYSE:COL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts